公开(公告)号：US20230123802A1

公开(公告)日：2023-04-20

申请号：US17598154

申请日：2020-03-27

Applicant: SIGILON THERAPEUTICS, INC.

Inventor： Lauren Emily Barney ,  Michael Beauregard ,  Guillaume Carmona ,  Francisco Caballero Gonzalez ,  Richard Heidebrecht ,  Erika Ellen Johnston ,  Robert James Miller ,  Owen O'Connor ,  Matthias Alexander Oberli ,  David Peritt ,  Jared A. Sewell ,  Devyn McKinley Smith ,  Omid Veiseh ,  Paul Kevin Wotton ,  Zoe Yin

IPC: A61K35/30 ,  A61K9/48 ,  C12N9/64 ,  C12N15/52 ,  C12N5/079

Abstract: Described herein are RPE cells engineered to secrete a FVII protein, as well as compositions, pharmaceutical preparations, and implantable devices comprising the engineered RPE cells, and methods of making and using the same for treating a patient with hemophilia or FVII deficiency.

公开(公告)号：US20210145759A1

公开(公告)日：2021-05-20

申请号：US17045127

申请日：2019-03-27

Applicant: SIGILON THERAPEUTICS, INC.

Inventor： Lauren Emily Barney ,  Michael Beauregard ,  Guillaume Carmona ,  Francisco Caballero Gonzalez ,  Richard Heidebrecht ,  Erika Ellen Johnston ,  Robert James Miller ,  Matthias Alexander Oberli ,  Owen O'Connor ,  David Peritt ,  Jared A. Sewell ,  Devyn McKinley Smith ,  Omid Veiseh ,  Paul Kevin Wotton

IPC: A61K9/50 ,  A61K35/28 ,  A61K35/30 ,  C07K14/755 ,  C07K14/62 ,  C12N9/64

Abstract: Described herein are particles comprising a first compartment, a second compartment, and a compound of Formula (I), as well as compositions and methods of making and using the same. The particles may comprise a cell capable of expressing a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.

公开(公告)号：US20200263196A1

公开(公告)日：2020-08-20

申请号：US16651892

申请日：2018-09-27

Applicant: SIGILON THERAPEUTICS, INC.

Inventor： Guillaume Carmona ,  Francisco Caballero Gonzalez ,  Richard Heidebrecht ,  Robert James Miller ,  Matthias Alexander Oberli ,  David Peritt ,  Jared A. Sewell ,  Devyn McKinley Smith ,  Omid Veiseh ,  Paul Kevin Wotton

IPC: C12N15/85 ,  C12N5/079 ,  A61K35/30 ,  C07K14/755 ,  C07K14/55 ,  C07K14/635 ,  A61K9/00 ,  A61K9/48 ,  A61K47/54

Abstract: Described herein are cell compositions comprising an active cell (e.g., an engineered active cell, e.g., an engineered RPE cell) or derivatives thereof, as well as compositions, pharmaceutical products, and implantable elements comprising an active cell, and methods of making and using the same. The cells and compositions may express a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.

公开(公告)号：US20250000788A1

公开(公告)日：2025-01-02

申请号：US18274134

申请日：2022-01-26

Applicant: SIGILON THERAPEUTICS, INC.

Inventor： Sofia Brites Boss ,  Christopher P. Hencken ,  Hozefa Bandukwala ,  Robert James Miller ,  Omid Veiseh ,  Devyn McKinley Smith

IPC: A61K9/00 ,  A61K9/50 ,  A61K31/5685 ,  A61K31/573 ,  A61K31/58 ,  A61K35/545 ,  A61K38/13 ,  A61K38/17 ,  A61K38/20 ,  A61K47/61 ,  A61K47/69

Abstract: Described herein are implantable devices comprising living cells and an extended release formulation of a glucocorticoid.

公开(公告)号：US20210145889A1

公开(公告)日：2021-05-20

申请号：US17045137

申请日：2019-03-27

Applicant: SIGILON THERAPEUTICS, INC.

Inventor： Devyn McKinley Smith ,  David Peritt ,  Omid Veiseh ,  Richard Heidebrecht ,  Robert James Miller

IPC: A61K35/28 ,  A61K9/00 ,  A61K47/22 ,  A61K9/50 ,  A61L27/38 ,  A61K38/37 ,  A61K38/48 ,  C12N5/00 ,  A61K38/28 ,  C12N5/0775

Abstract: Described herein are cell compositions comprising a mesenchymal stem function cell (MSFC), e.g., an engineered MSFC or derivatives thereof, as well as compositions, pharmaceutical products, and implantable elements comprising an MSFC, and methods of making and using the same. The cells and compositions may express a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.

公开(公告)号：US12161760B2

公开(公告)日：2024-12-10

申请号：US17045127

申请日：2019-03-27

Applicant: SIGILON THERAPEUTICS, INC.

Inventor： Lauren Emily Barney ,  Michael Beauregard ,  Guillaume Carmona ,  Francisco Caballero Gonzalez ,  Richard Heidebrecht ,  Erika Ellen Johnston ,  Robert James Miller ,  Matthias Alexander Oberli ,  Owen O'Connor ,  David Peritt ,  Jared A. Sewell ,  Devyn McKinley Smith ,  Omid Veiseh ,  Paul Kevin Wotton

IPC: A61K9/50 ,  A61K35/28 ,  A61K35/30 ,  C07K14/62 ,  C07K14/755 ,  C12N9/64

Abstract: Described herein are particles comprising a first compartment, a second compartment, and a compound of Formula (I), as well as compositions and methods of making and using the same. The particles may comprise a cell capable of expressing a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.

公开(公告)号：US20220267794A1

公开(公告)日：2022-08-25

申请号：US17598176

申请日：2020-03-27

Applicant: SIGILON THERAPEUTICS, INC.

Inventor： Lauren Emily Barney ,  Michael Beauregard ,  Guillaume Carmona ,  Francisco Caballero Gonzalez ,  Richard Heidebrecht ,  Erika Ellen Johnston ,  Robert James Miller ,  Owen O'Connor ,  Matthias Alexander Oberli ,  David Peritt ,  Jared A. Sewell ,  Devyn McKinley Smith ,  Omid Veiseh ,  Jeffrey Charles Way ,  Paul Kevin Wotton ,  Zoe Yin ,  Elina Makino ,  Brian Richard Fluharty ,  Marianthi Papakosta

IPC: C12N15/85 ,  A61K38/47 ,  A61K47/22 ,  A61K9/50 ,  C08L5/04

Abstract: Described herein are RPE cells engineered to secrete a GLA protein, as well as compositions, pharmaceutical preparations, and implantable devices comprising the engineered RPE cells, and methods of making and using the same for treating Fabry disease.

公开(公告)号：US20220000789A1

公开(公告)日：2022-01-06

申请号：US17280802

申请日：2019-09-27

Applicant: SIGILON THERAPEUTICS, INC.

Inventor： Lauren Emily Barney ,  Michael Beauregard ,  Guillaume Carmona ,  Francisco Caballero Gonzalez ,  Richard Heidebrecht ,  Erika Ellen Johnston ,  Robert James Miller ,  Owen O'Connor ,  Matthias Alexander Oberli ,  David Peritt ,  Jared A. Sewell ,  Devyn McKinley Smith ,  Omid Veiseh ,  Paul Kevin Wotton ,  Zoe Yin

IPC: A61K9/50 ,  A61K35/30 ,  A61K38/37

Abstract: Described herein are implantable devices comprising means for mitigating the foreign body response (FBR) and at least one cell-containing compartment which comprises a plurality of cells (e.g., live cells) encapsulated in a polymer composition comprising a cell-binding substance (CBS), as well as compositions and methods of making and using the same. The cells are capable of expressing a therapeutic agent useful for the treatment of a disease, disorder, or condition described herein.